Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.63 USD
+0.37 (1.46%)
Updated May 10, 2024 04:00 PM ET
After-Market: $25.58 -0.05 (-0.20%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -82.67 | -14.86 | 4.13 | -23.98 | 27.19 |
Depreciation/Amortization & Depletion | 76.41 | 14.49 | 20.78 | 69.52 | 6.36 |
Net Change from Assets/Liabilities | -12.12 | -11.82 | -11.96 | -12.94 | -6.64 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 16.60 | 16.60 | -4.56 | -19.54 | 10.10 |
Net Cash From Operating Activities | -1.79 | 4.41 | 8.40 | 13.07 | 37.01 |
Property & Equipment | -5.43 | -7.49 | -5.14 | -1.63 | -2.83 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -0.48 | -94.60 | 0.00 |
Investments | 0.00 | 0.00 | 2.50 | 24.97 | 42.52 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -5.43 | -7.49 | -3.12 | -71.26 | 39.69 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -4.98 | 0.02 | 1.13 | 1.52 | -7.85 |
Issuance (Repayment) of Debt | 0.00 | -0.28 | -0.20 | -0.56 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.35 | -4.58 | -7.71 | -4.74 | -0.29 |
Net Cash from Financing Activities | -6.32 | -4.85 | -6.78 | -3.77 | -8.14 |
Effect of Exchange Rate Changes | 0.08 | -0.13 | 0.07 | 0.33 | -0.13 |
Net Change In Cash & Equivalents | -13.46 | -8.06 | -1.43 | -61.65 | 68.42 |
Cash at Beginning of Period | 86.33 | 94.39 | 95.82 | 157.46 | 89.04 |
Cash at End of Period | 72.87 | 86.33 | 94.39 | 95.82 | 157.46 |
Diluted Net EPS | -5.64 | -1.02 | 0.28 | -1.69 | 1.89 |
Fiscal Year End for Anika Therapeutics Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -82.67 | -19.67 | -13.09 | -10.35 |
Depreciation/Amortization & Depletion | NA | 76.41 | 10.64 | 7.10 | 3.55 |
Net Change from Assets/Liabilities | NA | -12.12 | -9.51 | -12.95 | 0.64 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 16.60 | 13.11 | 7.03 | 2.54 |
Net Cash From Operating Activities | NA | -1.79 | -5.43 | -11.91 | -3.62 |
Property & Equipment | NA | -5.43 | -3.59 | -2.85 | -1.39 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -5.43 | -3.59 | -2.85 | -1.39 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -4.98 | -4.96 | -4.96 | 0.01 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -1.35 | -1.70 | -1.59 | -1.62 |
Net Cash from Financing Activities | NA | -6.32 | -6.67 | -6.56 | -1.61 |
Effect of Exchange Rate Changes | NA | 0.08 | 0.00 | 0.06 | 0.03 |
Net Change In Cash & Equivalents | NA | -13.46 | -15.68 | -21.26 | -6.59 |
Cash at Beginning of Period | NA | 86.33 | 86.33 | 86.33 | 86.33 |
Cash at End of Period | NA | 72.87 | 70.65 | 65.07 | 79.74 |
Diluted Net EPS | NA | -4.29 | -0.45 | -0.19 | -0.71 |